Abstract
Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.
| Original language | English |
|---|---|
| Journal | American Journal of Kidney Diseases |
| DOIs | |
| Publication status | Accepted/In press - 2017 |
Fingerprint
Keywords
- 177-Lu-DOTATATE
- Cancer
- Case report
- Gitelman
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Nephrotoxicity
- Neuroendocrine tumors (NETs)
- Peptide receptor radionuclide therapy (PRRT)
- Radiometabolic
- Tubulopathy
- Urine electrolytes
ASJC Scopus subject areas
- Nephrology
Cite this
Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome. / Negro, Aurelio; Rossi, Giovanni M.; Nicoli, Davide; Versari, Annibale; Farnetti, Enrico; Santi, Rosaria; De Pietri, Stefano.
In: American Journal of Kidney Diseases, 2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome
AU - Negro, Aurelio
AU - Rossi, Giovanni M.
AU - Nicoli, Davide
AU - Versari, Annibale
AU - Farnetti, Enrico
AU - Santi, Rosaria
AU - De Pietri, Stefano
PY - 2017
Y1 - 2017
N2 - Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.
AB - Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.
KW - 177-Lu-DOTATATE
KW - Cancer
KW - Case report
KW - Gitelman
KW - Hypocalcemia
KW - Hypokalemia
KW - Hypomagnesemia
KW - Nephrotoxicity
KW - Neuroendocrine tumors (NETs)
KW - Peptide receptor radionuclide therapy (PRRT)
KW - Radiometabolic
KW - Tubulopathy
KW - Urine electrolytes
UR - http://www.scopus.com/inward/record.url?scp=85025142469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025142469&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2017.05.024
DO - 10.1053/j.ajkd.2017.05.024
M3 - Article
AN - SCOPUS:85025142469
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
SN - 0272-6386
ER -